Avexitide delivered a highly differentiated phase 3 profile (initial thoughts here), with a 55% placebo-adjusted reduction in Level 2/3 events (p=0.000003), consistent benefit across all secondary endpoints, and favorable safety. The topline result exceeded the bar (our preview here) for a highly clinically meaningful treatment effect established through our KOL conversations (here) and extends avexitide's record to six positive PBH studies. With the phase 3 dataset representing the final major NDA componen ...